17α-羟孕酮己酸酯未能降低复发性早产率:一项前瞻性队列研究
该前瞻性队列研究纳入2012年1月至2016年3月430例既往有≤35周早产史的连续孕妇,接受17α-羟孕酮己酸酯治疗,旨在评估其预防复发性早产≤35周的临床效果。整个队列复发性早产率为25%(N=106),与历史参考率16.8%相比P=1.0;三个次要结局均为阴性。治疗组妊娠期糖尿病发生率为13.4%,匹配对照组为8%(P=.001)。结论认为17α-羟孕酮己酸酯对预防复发性早产无效,且与妊娠期糖尿病发生率升高相关。
要点
- 整个队列复发性早产率25%(106例)与历史参考率16.8%相比P=1.0,差异无统计学意义。
- 无论既往早产次数或顺序如何,17α-羟孕酮己酸酯均未显著降低复发率。
- 治疗组妊娠期糖尿病发生率13.4% vs 匹配对照组8%(P=.001)。
核心结论
- 17α-羟孕酮己酸酯对预防复发性早产无效,且与妊娠期糖尿病发生率升高相关。
研究设计与样本
- 前瞻性队列研究,纳入2012年1月至2016年3月共430例既往有≤35周早产史的连续孕妇,均接受17α-羟孕酮己酸酯治疗。
- 主要结局为整个研究队列≤35周复发性早产率,与本研究人群历史参考率16.8%比较。
- 次要结局包括:既往早产次数和顺序对复发率的影响、复发与17α-羟孕酮己酸酯血浆浓度的关系、治疗对妊娠时长的影响。
主要发现
- 整个队列复发性早产率为25%(N=106),历史参考率为16.8%,P=1.0。
- 无论既往早产次数或顺序如何,17α-羟孕酮己酸酯均未显著降低复发率。
- 分娩≤35周与分娩较晚的孕妇之间,17α-羟孕酮己酸酯血浆浓度无差异(24周时P=.17;32周时P=.38)。
- 使用17α-羟孕酮己酸酯前复发性早产的孕周间隔为0.4±5.3周,使用后为0.1±4.7周(P=.63)。
- 治疗组妊娠期糖尿病发生率为13.4%,匹配对照组为8%(P=.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 17-alpha Hydroxyprogesterone caproate for prevention of recurrent preterm birth is recommended for use in the United States. OBJECTIVE: We sought to assess the clinical effectiveness of 17-alpha hydroxyprogesterone caproate to prevent recurrent preterm birth ≤35 weeks compared to similar births in our obstetric population prior to the implementation of 17-alpha hydroxyprogesterone caproate. STUDY DESIGN: This was a prospective cohort study of 17-alpha hydroxyprogesterone caproate in our obstetric population. The primary outcome was the recurrence of birth ≤35 weeks for the entire study cohort compared to a historical referent rate of 16.8% of recurrent preterm birth in our population. There were 3 secondary outcomes. First, did 17-alpha hydroxyprogesterone caproate modify a woman's history of preterm birth when taking into account her prior number and sequence of preterm and term births? Second, was recurrence of preterm birth related to 17-alpha hydroxyprogesterone caproate plasma concentration? Third, was duration of pregnancy modified by 17-alpha hydroxyprogesterone caproate treatment compared to a prior preterm birth? RESULTS: From January 2012 through March 2016, 430 consecutive women with prior births ≤35 weeks were treated with 17-alpha hydroxyprogesterone caproate. Nearly two thirds of the women (N = 267) began injections ≤18 weeks and 394 (92%) received a scheduled weekly injection within 10 days of reaching 35 weeks or delivery. The overall rate of recurrent preterm birth was 25% (N = 106) for the entire cohort compared to the 16.8% expected rate (P = 1.0). The 3 secondary outcomes were also negative. First, 17-alpha hydroxyprogesterone caproate did not significantly reduce the rates of recurrence regardless of prior preterm birth number or sequence. Second, plasma concentrations of 17-alpha hydroxyprogesterone caproate were not different (P = .17 at 24 weeks; P = .38 at 32 weeks) between women delivered ≤35 weeks and those delivered later in pregnancy. Third, the mean (±SD) interval in weeks of recurrent preterm birth before 17-alpha hydroxyprogesterone caproate use was 0.4 ± 5.3 weeks and the interval of recurrent preterm birth after 17-alpha hydroxyprogesterone caproate treatment was 0.1 ± 4.7 weeks (P = .63). A side effect of weekly 17-alpha hydroxyprogesterone caproate injections was an increase in gestational diabetes. Specifically, the rate of gestational diabetes was 13.4% in 17-alpha hydroxyprogesterone caproate-treated women compared to 8% in case-matched controls (P = .001). CONCLUSION: 17-alpha Hydroxyprogesterone caproate was ineffective for prevention of recurrent preterm birth and was associated with an increased rate of gestational diabetes.
引用
- Nelson DB, McIntire DD, McDonald J, et al. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study. Am J Obstet Gynecol. 2017. PMID: 28223163. doi:10.1016/j.ajog.2017.02.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。